Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levosimendan - AbbVie/Tenax Therapeutics

Next Previous
Drug Profile

Levosimendan - AbbVie/Tenax Therapeutics

Alternative Names: Daxim; ODM 109; OR-1259; Simdax; TNX-101; TNX-102 - Tenax Therapeutics; TNX-103; TNX102

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orion
  • Developer Abbott Laboratories; AbbVie; Imperial College of Science, Technology and Medicine; Orion; Tenax Therapeutics; Yooyoung Pharmaceutical
  • Class Antiarrhythmics; Cardiotonics; Cardiovascular therapies; Hydrazones; Nitriles; Pyridazines; Small molecules; Vasodilators
  • Mechanism of Action Calcium binding protein modulators; Calcium-sensitising phosphodiesterase inhibitors; Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase III Amyotrophic lateral sclerosis; Chronic heart failure; Low cardiac output; Pulmonary hypertension
  • Discontinued Myocardial infarction; Septic shock; Stroke; Transient ischaemic attacks

Most Recent Events

  • 16 Sep 2025 The European Patent Office issues an intention to grant notification for patent application covering use of Levosimendan in Pulmonary hypertension with heart failure with preserved ejection fraction in Europe
  • 13 Aug 2025 Tenax Therapeutics plans phase III LEVEL 2 trial for Pulmonary hypertension in 2025
  • 01 Aug 2025 Tenax Therapeutics receives patent allowance for Levosimendan in Canada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top